Table 1.
Association between clinical characteristics and genotypes of rs2530223
| AA | GA/GG | Statistics | p value | Eta squared | |
|---|---|---|---|---|---|
| Women/men | 5/0 | 12/6 | 0.27 | ||
| Age (years) | 42.2 ± 10.9 | 43.1 ± 9.5 | 0.18 | 0.5 | |
| MOH duration | 3.9 ± 3.8 | 5.4 ± 3.6 | 0.81 | 0.37 | |
| Number of headache days/month | 18.6 ± 1.8 | 21.9 ± 4.1 | 3.04 | 0.09 | 0.12 |
| Headache intensity | 2.0 ± 0.7 | 2.2 ± 0.6 | 0.44 | 0.51 | 0.02 |
| Number of drugs/month abused | 14.2 ± 4.1 | 23.8 ± 6.7 | 9.47 | 0.006 | 0.30 |
| Days/month of drug abuse | 11.4 ± 2.6 | 19.0 ± 5.3 | 9.06 | 0.007 | 0.31 |
| VPA responders/nonresponders | 4/1 | 9/9 | – | 0.33 |
Continuous data are expressed in mean ± standard deviation; dichotomous data are expressed as frequencies
Headache intensity was measured with a 4-point scale with 0 = no pain, 1 = mild headache, 2 = moderate headache, 3 = severe headache. Headache attacks and drugs used during the baseline period were collected using a headache diary. Additional information on how these variables were collected is available in Sarchielli et al., 2014 [22]. Significant variables are indicated in bold
MOH medication overuse headache, VPA sodium valproate